Zanidatamab, a novel bispecific antibody, for the treatment of …
网页2022年11月15日 · Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. The aim of this study was to evaluate the safety and anti-tumour activity of zanidatamab across a range of solid tumours with HER2 expression or amplification.
An anti-HER2 biparatopic antibody that induces unique HER2
网页2023年3月13日 · Zanidatamab binds adjacent HER2 molecules in trans and initiates distinct HER2 reorganization, as shown by polarized cell surface HER2 caps and large HER2 clusters, not observed with trastuzumab...
Zanidatamab (zani), a HER2-targeted bispecific antibody, in …
网页Zani, also known as ZW25, is a novel HER2-targeted bispecific antibody that binds to two distinct extracellular domains of HER2. In a Phase 1 trial (NCT02892123) zani was well tolerated and demonstrated preliminary antitumor activity as monotherapy/with chemotherapy in pts with pre-treated advanced HER2+ breast cancer.
Zanidatamab Demonstrates Meaningful Clinical Benefit with...
网页2023年6月7日 · In a global, multicentre, single-arm, phase IIb HERIZON-BTC-01 study, zanidatamab showed meaningful activity, including rapid and durable responses, with a favourable safety profile in the treatment of patients with HER2 -positive biliary tract cancer with disease progression on previous gemcitabine-based therapy.
Zanidatamab for HER2-amplified, unresectable, locally advanced …
网页Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer.
Zanidatamab for HER2-amplified, unresectable, locally advanced …
网页2023年6月2日 · Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer. Methods.
Zanidatamab for HER2-amplified, unresectable, locally advanced …
网页2023年6月2日 · Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer.
Zanidatamab + chemotherapy as first-line treatment for HER2 …
网页2023年1月24日 · Background: Zanidatamab (zani) is an anti-HER2 bispecific antibody against ECD4 and ECD2 with demonstrated activity and tolerability in a range of HER2-expressing cancers. This Phase (Ph) 2 study (NCT03929666) evaluates zani in combination with chemotherapy (chemo) as first-line treatment for patients (pts) with advanced HER2 …
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab …
网页2024年9月16日 · Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free ...
First-Line Zanidatamab Plus Chemotherapy for HER2 ... - ASCO Post
网页2023年1月20日 · The data demonstrated zanidatamab combined with standard chemotherapy is a highly active treatment regimen for first-line therapy of HER2-positive metastatic gastroesophageal adenocarcinoma.
- 一些您可能无法访问的结果已被隐去。显示无法访问的结果